Table 3.
Univariate and multivariate Cox regression analyses of variables potentially associated with PFS.
| Variables | Patients | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | ||
| Age | 0.88 | 0.33-2.93 | 0.807 | ||||
| ≤ 60 years | 9 | ||||||
| >60 years | 13 | ||||||
| Gender | 0.22 | 0.06-0.82 | 0.024 | 3.19 | 0.71-14.29 | 0.129 | |
| male | 13 | ||||||
| female | 9 | ||||||
| Diameter of index tumor | 2.71 | 0.80-9.21 | 0.109 | ||||
| ≤ 3 cm | 18 | ||||||
| >3cm | 4 | ||||||
| Histological type | 1.28 | 0.87-1.88 | 0.203 | ||||
| pulmonary adenocarcinoma | 13 | ||||||
| pulmonary squamous cell carcinoma | 3 | ||||||
| small cell lung cancer | 1 | ||||||
| metastatic lung cancer | 5 | ||||||
| Primary | 0.49 | 0.157-1.53 | 0.218 | ||||
| Yes | 17 | ||||||
| No | 5 | ||||||
| Stage | 4.26 | 0.88-20.71 | 0.073 | 5.15 | 0.52-51.23 | 0.162 | |
| I | 3 | ||||||
| II | 2 | ||||||
| III | 4 | ||||||
| IV | 12 | ||||||
| PS | 1.98 | 1.15-3.42 | 0.014 | 1.44 | 0.76-2.75 | 0.264 | |
| 0 | 7 | ||||||
| 1 | 3 | ||||||
| 2 | 9 | ||||||
| 3 | 3 | ||||||
| Other treatment | 2.77 | 0.78-9.77 | 0.114 | ||||
| Yes | 15 | ||||||
| No | 7 | ||||||
| Technical efficacy | 0.31 | 0.10-0.97 | 0.044 | 0.73 | 0.21-2.56 | 0.62 | |
| Yes | 16 | ||||||
| No | 6 | ||||||
| Increase in CD8+ T cell proportion | 1.62 | 0.52-5.03 | 0.404 | ||||
| ≥ average | 9 | ||||||
| <average | 13 | ||||||
| Reduction in Treg cells proportion | 3.302 | 1.06-10.25 | 0.039 | 4.97 | 1.32-18.67 | 0.018 | |
| ≥ average | 8 | ||||||
| <average | 14 | ||||||
| Reduction in IL-2 level | 0.43 | 0.15-1.25 | 0.122 | ||||
| ≥ average | 11 | ||||||
| <average | 11 | ||||||
CI, confidence interval; HR, hazard ratio; IL, interleukin; PS, performance status; Treg, regulatory T cell.